BPC-157
Tissue Repair and Healing
ABOUT
BPC-157 is a synthetic pentadecapeptide being investigated in preclinical and very small human studies. A 2024 single-site pilot report in 12 participants is available, but it does not establish effectiveness or general safety.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
BPC-157 is a synthetic 15-amino-acid sequence taken from a protein found in human gastric juice. Animal work attributes its effects to angiogenesis and to activation of the FAK-paxillin pathway in tendon fibroblasts, alongside broad cytoprotection across gut, tendon and bone tissue. No receptor has been identified.
PHARMACOKINETICS
No pharmacokinetic study in humans has been published. Absorption, distribution, half-life and elimination are therefore unknown, and the stability claims made for oral preparations rest on rodent data rather than human measurement.
REVIEW
PUBLISHED PAIR RECORDS
with TB-500
Commonly combined tissue-repair peptides with no combination evidenceBPC-157 and TB-500 are frequently used together for tissue repair, and this is one of the few combinations in this catalogue with any human report at all: a retrospective chart review of knee-pain patients administered both together. That report had no control group, no randomisation, and cannot separate the contribution of either peptide - so it documents that the combination has been used, not that it works. A 2025 systematic review found one clinical study against 35 preclinical animal studies for BPC-157. Neither compound has a published human pharmacokinetic profile, so no exposure-based reasoning about combining them is possible. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Thymosin Beta-4
Commonly combined tissue-repair peptides with no combination evidenceBPC-157 and Thymosin beta-4 are frequently used together for tissue repair, and this is one of the few combinations in this catalogue with any human report at all: a retrospective chart review of knee-pain patients administered both together. That report had no control group, no randomisation, and cannot separate the contribution of either peptide - so it documents that the combination has been used, not that it works. A 2025 systematic review found one clinical study against 35 preclinical animal studies for BPC-157. Neither compound has a published human pharmacokinetic profile, so no exposure-based reasoning about combining them is possible. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with KLOW
Same substance taken twice: blend already contains this compoundKLOW already contains BPC-157 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GLOW
Same substance taken twice: blend already contains this compoundGLOW already contains BPC-157 at 10 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Wolverine blend
Same substance taken twice: blend already contains this compoundWolverine blend already contains BPC-157. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
The evidence base is almost entirely rodent. A 2025 systematic review screened 544 articles and found one clinical study against 35 preclinical animal studies. The human reports that do exist come from a single group and are uncontrolled: a retrospective chart review of patients given intra-articular knee injections, and a 2024 pilot study in interstitial cystitis. Neither was randomised or blinded. A phase 1 safety and pharmacokinetics trial (NCT02637284, 42 healthy volunteers) was registered in 2015 and cancelled in 2016 without published results.
REPORTED EFFECTS
Few adverse events have been reported, but that reflects the near-absence of human study rather than demonstrated safety: with no completed controlled trial, the rate of uncommon or delayed harms is unmeasured. Material sold outside a pharmacy is not made to a purity standard. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
Human evidence is sparse, uncontrolled, and not sufficient to establish safety or effectiveness. This record is not an approval, a protocol, or a recommendation; product quality and regulatory status require independent verification.
CURATED SOURCES · 6